Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
•
Medical Oncology
•
Breast Cancer, Metastatic
Are you comfortable combining palliative radiotherapy with capivasertib/fulvestrant?
Any pitfalls to be aware of?
Answer from: Medical Oncologist at Community Practice
Yes. Follow CBC
Sign In
or
Register
to read more
22945
Related Questions
What are your top takeaways in Medical Oncology from SABCS 2024?
What are your top takeaways in Radiation Oncology from SABCS 2024?
What are your top takeaways in Breast Cancer from ASCO 2025?
Do you continue ovarian suppression for metastatic hormone-positive breast cancer patients who are premenopausal, regardless of line of therapy?
How do you reconcile data from the PATINA trial and DESTINY-Breast09 with respect to CDK4/6 inhibitor maintenance in metastatic ER+ HER2+ breast cancer?
What factors should be considered when deciding between datopotamab deruxtecan and sacituzumab govitecan for a patient with metastatic breast cancer?
In patients with advanced HR+, HER2- breast cancer who have progressed on first-line CDK 4/6i and ET and found to have ESR1 mutation, are you offering combination of abemaciclib and elacestrant in the 2nd line or SERD monotherapy?
How would you approach a patient with metastatic high grade neuroendocrine carcinoma of the breast which is HR+ HER2 negative?
When do you start adjuvant radiation with areas of delayed wound healing after reduction mammoplasty?
What treatment would you recommend for a patient with early-stage TNBC treated per KEYNOTE-522, PD-L1 CPS >10, with metastatic recurrence within 12 months of treatment completion?